Clinical Trial Update: Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury [Phase 4]

View source ↗

Summary

Phase 4 trial assessing dapagliflozin to prevent acute kidney injury after percutaneous coronary intervention has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Albert Einstein Healthcare Network | Conditions: Acute Kidney Injury, Percutaneous Coronary Intervention | Phase 4 | Status: SUSPENDED